PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: PIPELINE ANALYSIS • Pipeline analysis PART 06: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 07: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 08: MARKET SEGMENTATION BY TARGET DISEASE FOR IMMUNIZATION • Segmentation by target disease for immunization • Comparison by target disease for immunization • Influenza – Market size and forecast 2017-2022 • Diphtheria – Market size and forecast 2017-2022 • Others – Market size and forecast 2017-2022 • Hepatitis – Market size and forecast 2017-2022 • Typhoid – Market size and forecast 2017-2022 • Polio – Market size and forecast 2017-2022 • Yellow fever – Market size and forecast 2017-2022 • Market opportunity by target disease PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity by region PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Changes in the demographic profile of travelers globally • Increased incidence of travel-related diseases • Initiatives by governments and other organizations to ensure travel safety • Evolving epidemiological patterns of infectious diseases in different countries PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • GlaxoSmithKline • Pfizer • Sanofi • Valneva PART 16: APPENDIX • List of abbreviations Exhibit 01: Parent market Exhibit 02: Global human vaccines market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Pipeline Vaccines Under Phase III Development Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2017 Exhibit 08: Validation techniques employed for market sizing 2017 Exhibit 09: Global – Market size and forecast 2017-2022 ($ mn) Exhibit 10: Global – Year-over-year growth 2018-2022 (%) Exhibit 11: Five forces analysis 2017 Exhibit 12: Five forces analysis 2022 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2017 Exhibit 19: Target disease for immunization – Market share 2017-2022 (%) Exhibit 20: Comparison by target disease for immunization Exhibit 21: Influenza – Market size and forecast 2017-2022 ($ mn) Exhibit 22: Influenza – Year-over-year growth 2018-2022 (%) Exhibit 23: Diphtheria – Market size and forecast 2017-2022 ($ mn) Exhibit 24: Diphtheria – Year-over-year growth 2018-2022 (%) Exhibit 25: Others – Market size and forecast 2017-2022 ($ mn) Exhibit 26: Others – Year-over-year growth 2018-2022 (%) Exhibit 27: Hepatitis – Market size and forecast 2017-2022 ($ mn) Exhibit 28: Hepatitis – Year-over-year growth 2018-2022 (%) Exhibit 29: Typhoid – Market size and forecast 2017-2022 ($ mn) Exhibit 30: Typhoid – Year-over-year growth 2018-2022 (%) Exhibit 31: Polio – Market size and forecast 2017-2022 ($ mn) Exhibit 32: Polio – Year-over-year growth 2018-2022 (%) Exhibit 33: Yellow fever – Market size and forecast 2017-2022 ($ mn) Exhibit 34: Yellow fever – Year-over-year growth 2018-2022 (%) Exhibit 35: Market opportunity by target disease for immunization Exhibit 36: Customer landscape Exhibit 37: Global – Market share by geography 2017-2022 (%) Exhibit 38: Regional comparison Exhibit 39: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 40: Americas – Year-over-year growth 2018-2022 (%) Exhibit 41: Top 3 countries in Americas Exhibit 42: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 43: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 44: Top 3 countries in EMEA Exhibit 45: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 46: APAC – Year-over-year growth 2018-2022 (%) Exhibit 47: Top 3 countries in APAC Exhibit 48: Market opportunity Exhibit 49: Vendor landscape Exhibit 50: Landscape disruption Exhibit 51: Vendors covered Exhibit 52: Vendor classification Exhibit 53: Market positioning of vendors Exhibit 54: GlaxoSmithKline – Overview Exhibit 55: GlaxoSmithKline – Business segments Exhibit 56: GlaxoSmithKline – Organizational developments Exhibit 57: GlaxoSmithKline – Geographic focus Exhibit 58: GlaxoSmithKline – Segment focus Exhibit 59: GlaxoSmithKline – Key offerings Exhibit 60: Pfizer – Overview Exhibit 61: Pfizer – Business segments Exhibit 62: Pfizer – Organizational developments Exhibit 63: Pfizer – Geographic focus Exhibit 64: Pfizer – Segment focus Exhibit 65: Pfizer – Key offerings Exhibit 66: Sanofi – Overview Exhibit 67: Sanofi – Business segments Exhibit 68: Sanofi – Organizational developments Exhibit 69: Sanofi – Geographic focus Exhibit 70: Sanofi – Segment focus Exhibit 71: Sanofi – Key offerings Exhibit 72: Valneva – Overview Exhibit 73: Valneva– Business segments Exhibit 74: Valneva – Organizational developments Exhibit 75: Valneva – Geographic focus Exhibit 76: Valneva – Key offerings  

GlaxoSmithKline Pfizer Sanofi Valneva